"The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, ensuring a maximum level of interaction between faculty and registered participants.
Chairs: Caron Jacobson, Ulrich Jäger, Marie José Kersten"
"CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies.
The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.
The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.
In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, authorities and industry.
Continuing Medical Education (CME) credit points will be awarded to physicians for the time they will spend at the meeting improving their knowledge and skills. ESH is a provider of the European Hematology CME system.
Posters and Brief Oral Communications:
Registered participants are invited to submit their clinical cases and abstracts abstracts. Selected clinical cases and abstracts will be presented as brief oral communications or posters.
Call for abstracts and clinical cases: June 29, 2025 (23:59 CEST)
The meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior scientists and clinicians (MD, PhD)
• PhD candidates and clinical residents still in-training
Conference Main Scientific Topics:
- Non-hodgkin lymphoma
- Multiple myeloma
- Novel indications of CAR T-cell therapy
- 1st line high-risk large B-cell lymphoma
- Access to CAR-T and bispecific across the globe
- Predictors of response and toxicity of CAR and bispecific
- Access issues in CAR T-cell treatment
- CAR-T vs bispecific antibody in multiple myeloma
- Real world data for CAR-T and bispecific
- Next Generation of CAR T-cell and bispecific antibody therapy
The programme will include:
– Keynote Lecture
– Plenary Sessions
– Meet the Expert Sessions
– Roundtables
– Debates
– Mentored Poster Walks
– Brief Oral Communications
– Voting technology
To register for this event: https://www.esh.org/conference/3rd-how-i-manage-car-t-therapies-and-bispecific-antibodies-for-my-patients
For queries please email: [email protected]
